<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05085561</url>
  </required_header>
  <id_info>
    <org_study_id>REC-994-201</org_study_id>
    <nct_id>NCT05085561</nct_id>
  </id_info>
  <brief_title>The Symptomatic Cerebral Cavernous Malformation Trial of REC-994</brief_title>
  <acronym>SYCAMORE</acronym>
  <official_title>A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of REC-994 in the Treatment of Symptomatic Cerebral Cavernous Malformation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Recursion Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Recursion Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double-blind, placebo-controlled study to investigate the&#xD;
      safety, efficacy and pharmacokinetics of REC-994 (200 mg and 400 mg) compared to placebo in&#xD;
      subjects with symptomatic cerebral cavernous malformation (CCM).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events (AEs)</measure>
    <time_frame>12 months</time_frame>
    <description>Safety and tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in laboratory assessments (hematology, chemistry, coagulation, and urinalysis), 12-lead ECGs, vital sign measurements, and physical examinations.</measure>
    <time_frame>12 months</time_frame>
    <description>Safety and tolerability</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cerebral Cavernous Malformation</condition>
  <arm_group>
    <arm_group_label>REC-994 200 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>REC-994 200 mg po once daily (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>REC-994 400 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>REC-994 400 mg po QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo po QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REC-994</intervention_name>
    <description>REC-994 200 mg tablets</description>
    <arm_group_label>REC-994 200 mg</arm_group_label>
    <arm_group_label>REC-994 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Tablets</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>REC-994 200 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. 18 years of age or older with anatomic CCM lesions demonstrated by brain MRI&#xD;
&#xD;
          2. Have symptomatic CCM&#xD;
&#xD;
          3. Have provided written informed consent to participate in the study&#xD;
&#xD;
          4. Have NOT participated in a clinical trial utilizing an investigational agent within 28&#xD;
             days or within 6 half-lives of the investigational drug (whichever is longer) prior to&#xD;
             Screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Symptoms deemed by the study Investigator to be caused exclusively by irreversible&#xD;
             neuronal damage from prior stroke or neurosurgical instrumentation&#xD;
&#xD;
          2. History of cranial irradiation or surgical/radiosurgical treatment of the primary&#xD;
             symptomatic CCM lesion&#xD;
&#xD;
          3. Pregnant or breast feeding&#xD;
&#xD;
          4. Unable or unwilling to participate in MRI assessments (eg, claustrophobia, metal&#xD;
             implant, implanted cardiac pacemaker, allergy to gadolinium)&#xD;
&#xD;
          5. Liver dysfunction or active liver disease as defined by baseline serum transaminases&#xD;
             &gt;2x upper limit of normal (ULN)&#xD;
&#xD;
          6. Have severely impaired renal function (eGFR &lt;60ml/min) or active renal disease&#xD;
&#xD;
          7. Have had a previous diagnosis of skeletal muscle disorders (myopathy) of any cause or&#xD;
             have a baseline creatine kinase level &gt; 5x ULN&#xD;
&#xD;
          8. History of alcohol or substance abuse within 1 year prior to screening&#xD;
&#xD;
          9. Clinically significant laboratory abnormality&#xD;
&#xD;
         10. Have had an intracerebral hemorrhage within 3 months of screening or any brain surgery&#xD;
             within 6 months of screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rebecca Rynders, RN, MS</last_name>
    <phone>385-374-1724</phone>
    <email>clinicaltrials@recursionpharma.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 8, 2021</study_first_submitted>
  <study_first_submitted_qc>October 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2021</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemangioma, Cavernous, Central Nervous System</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

